Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Blood ; 96(4): 1393-8, 2000 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-10942383

RESUMO

Inflammation may contribute to the pathogenesis of atherosclerosis. On the basis of previous reports that human atherosclerotic lesions contain alpha-defensins, a class of cationic proteins released by activated neutrophils, the study was designed to ask whether defensins modulate the binding and catabolism of low-density lipoprotein (LDL) by human vascular cells. The results of the study demonstrated that defensin stimulated the binding of (125)I-LDL to cultured human umbilical vein endothelial cells, smooth muscle cells, and fibroblasts approximately 5-fold in a dose-dependent and saturable manner. Defensin and LDL formed stable complexes in solution and on cell surfaces. Stimulation of LDL binding by defensin was not inhibited by antibodies against the LDL-receptor (LDL-R), or by recombinant receptor-associated protein, which blocks binding of ligands to the alpha(2)-macroglobulin receptor/LDL-R-related protein and other LDL-R family members. Furthermore, defensin stimulated the binding, endocytosis, and degradation of LDL by fibroblasts lacking LDL-R. Stimulation of LDL degradation by defensin was inhibited approximately 75% by low concentrations of heparin (0.2 units/mL) and was similarly reduced in CHO cells lacking heparan-sulfate-containing proteoglycans. The effect of defensin was substantially increased in cells overexpressing the core protein of the syndecan-1 heparan sulfate proteoglycan. The alpha-defensins released from activated neutrophils may provide a link between inflammation and atherosclerosis by changing the pattern of LDL catabolism from LDL-R to the less efficient LDL-R-independent, proteoglycan-dependent pathway. (Blood. 2000;96:1393-1398)


Assuntos
Endotélio Vascular/metabolismo , Lipoproteínas LDL/metabolismo , Músculo Liso Vascular/metabolismo , Proteínas/farmacologia , Proteoglicanas/metabolismo , Receptores de LDL/metabolismo , Animais , Arteriosclerose/etiologia , Arteriosclerose/metabolismo , Proteínas Sanguíneas/metabolismo , Células CHO , Cricetinae , Defensinas , Relação Dose-Resposta a Droga , Humanos , Neutrófilos/metabolismo , Proteínas/metabolismo
2.
J Biol Chem ; 275(32): 24304-12, 2000 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-10801829

RESUMO

Urokinase-type plasminogen activator (uPA) binds to its receptor (uPAR) with a K(d) of about 1 nm. The catalytic activity of the complex is apparent at uPA concentrations close to K(d). Other functions of the complex, such as signal transduction, are apparent at much higher concentrations (35-60 nm). In the present study, we show that uPA and recombinant soluble uPAR (suPAR), at concentrations that exceed the K(d) and the theoretical saturation levels (10-80 nm), establish novel interactions that lead to a further increase in the activity of the single-chain uPA (scuPA)/suPAR and two-chain uPA (tcuPA)/suPAR complexes. Experiments performed using dynamic light scattering, gel filtration, and electron microscopy techniques indicate that suPAR forms dimers and oligomers. The three techniques provide evidence that the addition of an equimolar concentration of scuPA leads to the dissociation of these dimers and oligomers. Biacore data show that suPAR dimers and oligomers bind scuPA with decreased affinity when compared with monomers. We postulate that uPAR is present in equilibrium between oligomer/dimer/monomer forms. The binding of uPA to suPAR dimers and oligomers occurs with lower affinity than the binding to monomer. These novel interactions regulate the activity of the resultant complexes and may be involved in uPA/uPAR mediated signal transduction.


Assuntos
Receptores de Superfície Celular/química , Receptores de Superfície Celular/metabolismo , Ativador de Plasminogênio Tipo Uroquinase/química , Ativador de Plasminogênio Tipo Uroquinase/metabolismo , Fibrinólise , Humanos , Cinética , Luz , Microscopia Eletrônica , Plasminogênio/metabolismo , Receptores de Superfície Celular/ultraestrutura , Receptores de Ativador de Plasminogênio Tipo Uroquinase , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/ultraestrutura , Espalhamento de Radiação , Trombina/metabolismo , Ativador de Plasminogênio Tipo Uroquinase/ultraestrutura
3.
Blood ; 92(6): 2075-83, 1998 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-9731065

RESUMO

Single-chain urokinase plasminogen activator (scuPA), the unique form secreted by cells, expresses little intrinsic plasminogen activator activity. scuPA can be activated by proteolytic cleavage to form a two-chain enzyme (tcuPA), which is susceptible to inhibition by plasminogen activator inhibitor type I (PAI-1). scuPA is also activated when it binds to its cellular receptor (uPAR), in which case the protein remains as a single chain molecule with less susceptibility to PAIs. Fibrin clots are invested with PAI-1 derived from plasma and from activated platelets. Therefore, we compared the fibrinolytic activity of complexes between scuPA and recombinant soluble uPAR (suPAR) to that of scuPA, tcuPA, and tcuPA/suPAR complexes. scuPA/suPAR complexes mediated the lysis of plasma-derived fibrin clots 14-fold more extensively than did equimolar concentrations of scuPA and threefold more extensively than did tcuPA or tcuPA/suPAR, respectively. The enhanced catalytic activity of scuPA/suPAR required that all three domains of the receptor be present, correlated with its PAI-1 resistance, was not dependent on fibrin alone, and required a plasma cofactor that was identified as IgG. Human IgG bound specifically to suPAR and scuPA/suPAR as determined by using affinity chromatography and immunoprecipitation. Plasma depleted of IgG lost most of its capacity to promote the fibrinolytic activity of scuPA/suPAR, and the activity of the complex was restored by adding plasma concentrations of purified IgG. These studies indicate that scuPA/suPAR can function as a plasminogen activator in a physiological milieu.


Assuntos
Coagulação Sanguínea/fisiologia , Fibrinólise , Receptores de Superfície Celular/fisiologia , Ativador de Plasminogênio Tipo Uroquinase/fisiologia , Sequência de Aminoácidos , Coagulação Sanguínea/efeitos dos fármacos , Coagulação Sanguínea/genética , Fibrinólise/efeitos dos fármacos , Fibrinólise/genética , Humanos , Imunoglobulina G/isolamento & purificação , Imunoglobulina G/fisiologia , Cadeias Pesadas de Imunoglobulinas/isolamento & purificação , Região Variável de Imunoglobulina/isolamento & purificação , Região Variável de Imunoglobulina/fisiologia , Dados de Sequência Molecular , Receptores de Superfície Celular/genética , Receptores de Ativador de Plasminogênio Tipo Uroquinase , Proteínas Recombinantes/farmacologia , Solubilidade , Ativador de Plasminogênio Tipo Uroquinase/genética
4.
Z Orthop Ihre Grenzgeb ; 125(3): 332-6, 1987.
Artigo em Alemão | MEDLINE | ID: mdl-3673185

RESUMO

The present article reports on the geometrical conditions of the physiological movement of the patella. The geometrical shape of 18 femoral condyles and patella sliding areas was investigated in order to describe basic data for the design of endoprostheses. Surface and direction of the facies patellaris femoris were determined by means of radiographic, mechanical and optical measurements. The curvature of the deepest patella sliding groove proves a constant correlation with the dorsal condylar curvature. In the frontal plane the lowest points of the sliding area run with a dispersion of +/- 4 degrees to the vertical line related to the transverse tangent on the dorsal condylar surface. Considering deviations of leg alignment the measures come close to an angle of about 0 degrees. So the direction of the patella sliding groove differs from the normal valgus position of the distal femur. Therefore in artificial knee replacement a lateral tilt of the patella sliding groove should not be propagated as 'physiological'.


Assuntos
Fêmur/anatomia & histologia , Patela/anatomia & histologia , Fenômenos Biomecânicos , Fêmur/fisiologia , Humanos , Interferometria , Prótese do Joelho , Patela/fisiologia , Fotogrametria
8.
Z Orthop Ihre Grenzgeb ; 118(3): 396-404, 1980.
Artigo em Alemão | MEDLINE | ID: mdl-7415434

RESUMO

Evaluation of 100 sagittal sections shows that all condyle shapes can be classified into 4 groups according to size, if we allow maximal +/- 1 mm for the distance of all points of an individual outline of condyle from the medial outline representative for a particular size group. Large and small condyles resemble each other and can, therefore, be matched by enlargement or reduction. The same mathematical adaptation function can be appied for medial and lateral condyles. The coordinate systems of the adaptation functions for the medial and lateral condyles are displaced against each other by rotation. The angle of rotation varies between 5 and 20 degrees. The center of rotation for all functions is the center of the largest circle which fits into the dorsal condyle region. For the medium size group, its radius is 19.8 mm. This circle produces best adaptation in the dorsal condyle region for the medial and lateral condyle. All functions are suitable for ventral adaptation of the curves to the condyles; however, proper choice of the system of coordinates is of decisive importance. The measurements support the assumption that, apart from pathological changes in the joint, condyles in different individuals are largely uniform in sagittal curvature, i.e. of similar shape.


Assuntos
Fêmur/anatomia & histologia , Fenômenos Biomecânicos , Humanos , Matemática
10.
Biochim Biophys Acta ; 478(1): 1-8, 1977 Sep 06.
Artigo em Inglês | MEDLINE | ID: mdl-407935

RESUMO

1-beta-D-Arabinofuranosyl cytosine (araC), a pyrimidine nucleoside analog used in the treatment of malignant tumors [1, 2], inhibits ultraviolet repair of DNA in a reversible manner. The inhibition occurs during the resynthesis-ligation step and is apparent at all sites undergoing repair. By use of araC it was possible to substantiate the reported observation that the initial velocities of ultraviolet repair are dose dependent and that hamster and human cells are more efficient that mouse cells in excising DNA damage after fluences of less than 50 J/m2. araC does not strongly inhibit gamma-ray-induced repair, although alkali-labile sites are removed more slowly in araC-treated cells. Repair of damage to DNA by N-methyl-N-nitrosoguanidine, mitomycin C, 4-nitroquinoline oxide and 8-hydroxyquinoline is strongly inhibited by araC.


Assuntos
Citarabina/farmacologia , Reparo do DNA/efeitos dos fármacos , DNA , 4-Nitroquinolina-1-Óxido/farmacologia , Linhagem Celular , Transformação Celular Neoplásica , DNA/efeitos da radiação , Raios gama , Mitomicinas/farmacologia , Nitrosoguanidinas/farmacologia , Oxiquinolina/farmacologia , Raios Ultravioleta
12.
Pflugers Arch ; 362(2): 141-6, 1976 Mar 30.
Artigo em Inglês | MEDLINE | ID: mdl-944421

RESUMO

The hypothesis that different receptor sites for algesic agents exist at free nerve endings in skeletal muscle has been tested by administering bradykinin and 5-hydroxytryptamine (5-HT) repeatedly in anaesthetized cats and evaluating the response behaviour of single group IV afferent units from the gastrocnemius-soleus muscle. Repeated intraarterial administration of bradykinin at intervals of 1 and 2 min usually elicited fibre responses without tachyphylaxis. Injections of equieffective doses of 5-HT, however, given in the same manner evoked fibre reactions that were strongly tachyphylactic. In units responding to both bradykinin and 5-HT a refractoriness to 5-HT could be induced by repeated injections of this agent without impairing the stimulating potency of bradykinin on the same nerve ending. Such a lack of cross-tachyphylaxis seems to apply also to the effects of histamine on one side and bradykinin or 5-HT on the other. These findings suggest that bradykinin, 5-HT and probably histamine exert their excitatory action on muscular group IV afferent units via different receptor sites.


Assuntos
Músculos/inervação , Terminações Nervosas/ultraestrutura , Dor , Células Receptoras Sensoriais/ultraestrutura , Animais , Bradicinina/farmacologia , Gatos , Eletrofisiologia , Histamina/farmacologia , Injeções Intra-Arteriais , Injeções Intramusculares , Neurônios Aferentes/fisiologia , Receptores de Droga , Serotonina/farmacologia , Taquifilaxia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...